GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gemina Laboratories Ltd (XCNQ:GLAB) » Definitions » Return-on-Tangible-Equity

Gemina Laboratories (XCNQ:GLAB) Return-on-Tangible-Equity : 0.00% (As of Jan. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Gemina Laboratories Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Gemina Laboratories's annualized net income for the quarter that ended in Jan. 2024 was C$-3.05 Mil. Gemina Laboratories's average shareholder tangible equity for the quarter that ended in Jan. 2024 was C$-1.13 Mil. Therefore, Gemina Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2024 was N/A%.

The historical rank and industry rank for Gemina Laboratories's Return-on-Tangible-Equity or its related term are showing as below:

XCNQ:GLAB's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -46.86
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Gemina Laboratories Return-on-Tangible-Equity Historical Data

The historical data trend for Gemina Laboratories's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gemina Laboratories Return-on-Tangible-Equity Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24
Return-on-Tangible-Equity
- -857.79 -1,371.33 -

Gemina Laboratories Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,618.20 -963.50 -794.96 - -

Competitive Comparison of Gemina Laboratories's Return-on-Tangible-Equity

For the Biotechnology subindustry, Gemina Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gemina Laboratories's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's Return-on-Tangible-Equity falls into.



Gemina Laboratories Return-on-Tangible-Equity Calculation

Gemina Laboratories's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jan. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jan. 2024 )  (A: Jan. 2023 )(A: Jan. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jan. 2024 )  (A: Jan. 2023 )(A: Jan. 2024 )
=-5.217/( (-0.072+-1.585 )/ 2 )
=-5.217/-0.8285
=N/A %

Gemina Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jan. 2024 )  (Q: Oct. 2023 )(Q: Jan. 2024 )
=-3.048/( (-0.67+-1.585)/ 2 )
=-3.048/-1.1275
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jan. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Gemina Laboratories  (XCNQ:GLAB) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Gemina Laboratories Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Gemina Laboratories's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Gemina Laboratories (XCNQ:GLAB) Business Description

Traded in Other Exchanges
Address
3800 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.
Executives
James Damian Tansey Director

Gemina Laboratories (XCNQ:GLAB) Headlines

No Headlines